Cystatin C and albuminuria as risk factors for development of CKD stage 3

The multi-ethnic study of atherosclerosis (MESA)

Shani Shastri, Ronit Katz, Michael G. Shlipak, Bryan Kestenbaum, Carmen A. Peralta, Holly Kramer, David R. Jacobs, Ian H. De Boer, Mary Cushman, David Siscovick, Mark J. Sarnak

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: The growing burden and morbidity of chronic kidney disease (CKD) warrant effective strategies for identifying those at increased risk. We examined the association of cystatin C level and albuminuria with the development of CKD stage 3. Study Design: Prospective observational study. Setting & Participants: 5,422 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Predictor: Participants were categorized into 4 mutually exclusive groups: the presence or absence of microalbuminuria (albumin-creatinine ratio >17 and >25 μg/mg in men and women, respectively) in those with or without cystatin C level <1.0 mg/L. Outcomes & Measurements: Incident CKD stage 3 was defined as eGFR <60 mL/min/1.73 m2 at the third or fourth visit and an annual decrease >1 mL/min/1.73 m2. Poisson regression was used to evaluate incident rate ratios in unadjusted and adjusted analyses that include baseline eGFR. Results: Mean age was 61 years, 49% were men, 38% were white, 11% had diabetes, 13.7% had cystatin C level <1 mg/L, 8.4% had microalbuminuria, and 2.7% had cystatin C level <1 mg/L with microalbuminuria. 554 (10%) participants developed CKD stage 3 during a median follow-up of 4.7 years, and adjusted incidence rate ratios were 1.57 (95% CI, 1.19-2.07), 1.37 (95% CI, 1.13-1.66), and 2.12 (95% CI, 1.61-2.80) in those with microalbuminuria, cystatin C level <1 mg/L, and both, respectively, compared with those with neither. Limitations: Relatively short follow-up and absence of measured GFR. Conclusions: Cystatin C level and microalbuminuria are independent risk factors for incident CKD stage 3 and could be useful as screening tools to identify those at increased risk.

Original languageEnglish (US)
Pages (from-to)832-840
Number of pages9
JournalAmerican Journal of Kidney Diseases
Volume57
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Cystatin C
Albuminuria
Chronic Renal Insufficiency
Atherosclerosis
Glomerular Filtration Rate
Observational Studies
Prospective Studies
Morbidity
Incidence

Keywords

  • Albuminuria
  • chronic kidney disease
  • cystatin C
  • risk factors

ASJC Scopus subject areas

  • Nephrology

Cite this

Cystatin C and albuminuria as risk factors for development of CKD stage 3 : The multi-ethnic study of atherosclerosis (MESA). / Shastri, Shani; Katz, Ronit; Shlipak, Michael G.; Kestenbaum, Bryan; Peralta, Carmen A.; Kramer, Holly; Jacobs, David R.; De Boer, Ian H.; Cushman, Mary; Siscovick, David; Sarnak, Mark J.

In: American Journal of Kidney Diseases, Vol. 57, No. 6, 06.2011, p. 832-840.

Research output: Contribution to journalArticle

Shastri, S, Katz, R, Shlipak, MG, Kestenbaum, B, Peralta, CA, Kramer, H, Jacobs, DR, De Boer, IH, Cushman, M, Siscovick, D & Sarnak, MJ 2011, 'Cystatin C and albuminuria as risk factors for development of CKD stage 3: The multi-ethnic study of atherosclerosis (MESA)', American Journal of Kidney Diseases, vol. 57, no. 6, pp. 832-840. https://doi.org/10.1053/j.ajkd.2010.11.021
Shastri, Shani ; Katz, Ronit ; Shlipak, Michael G. ; Kestenbaum, Bryan ; Peralta, Carmen A. ; Kramer, Holly ; Jacobs, David R. ; De Boer, Ian H. ; Cushman, Mary ; Siscovick, David ; Sarnak, Mark J. / Cystatin C and albuminuria as risk factors for development of CKD stage 3 : The multi-ethnic study of atherosclerosis (MESA). In: American Journal of Kidney Diseases. 2011 ; Vol. 57, No. 6. pp. 832-840.
@article{28b5d7cbd7d84eb0ae400a05eb6877f3,
title = "Cystatin C and albuminuria as risk factors for development of CKD stage 3: The multi-ethnic study of atherosclerosis (MESA)",
abstract = "Background: The growing burden and morbidity of chronic kidney disease (CKD) warrant effective strategies for identifying those at increased risk. We examined the association of cystatin C level and albuminuria with the development of CKD stage 3. Study Design: Prospective observational study. Setting & Participants: 5,422 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Predictor: Participants were categorized into 4 mutually exclusive groups: the presence or absence of microalbuminuria (albumin-creatinine ratio >17 and >25 μg/mg in men and women, respectively) in those with or without cystatin C level <1.0 mg/L. Outcomes & Measurements: Incident CKD stage 3 was defined as eGFR <60 mL/min/1.73 m2 at the third or fourth visit and an annual decrease >1 mL/min/1.73 m2. Poisson regression was used to evaluate incident rate ratios in unadjusted and adjusted analyses that include baseline eGFR. Results: Mean age was 61 years, 49{\%} were men, 38{\%} were white, 11{\%} had diabetes, 13.7{\%} had cystatin C level <1 mg/L, 8.4{\%} had microalbuminuria, and 2.7{\%} had cystatin C level <1 mg/L with microalbuminuria. 554 (10{\%}) participants developed CKD stage 3 during a median follow-up of 4.7 years, and adjusted incidence rate ratios were 1.57 (95{\%} CI, 1.19-2.07), 1.37 (95{\%} CI, 1.13-1.66), and 2.12 (95{\%} CI, 1.61-2.80) in those with microalbuminuria, cystatin C level <1 mg/L, and both, respectively, compared with those with neither. Limitations: Relatively short follow-up and absence of measured GFR. Conclusions: Cystatin C level and microalbuminuria are independent risk factors for incident CKD stage 3 and could be useful as screening tools to identify those at increased risk.",
keywords = "Albuminuria, chronic kidney disease, cystatin C, risk factors",
author = "Shani Shastri and Ronit Katz and Shlipak, {Michael G.} and Bryan Kestenbaum and Peralta, {Carmen A.} and Holly Kramer and Jacobs, {David R.} and {De Boer}, {Ian H.} and Mary Cushman and David Siscovick and Sarnak, {Mark J.}",
year = "2011",
month = "6",
doi = "10.1053/j.ajkd.2010.11.021",
language = "English (US)",
volume = "57",
pages = "832--840",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Cystatin C and albuminuria as risk factors for development of CKD stage 3

T2 - The multi-ethnic study of atherosclerosis (MESA)

AU - Shastri, Shani

AU - Katz, Ronit

AU - Shlipak, Michael G.

AU - Kestenbaum, Bryan

AU - Peralta, Carmen A.

AU - Kramer, Holly

AU - Jacobs, David R.

AU - De Boer, Ian H.

AU - Cushman, Mary

AU - Siscovick, David

AU - Sarnak, Mark J.

PY - 2011/6

Y1 - 2011/6

N2 - Background: The growing burden and morbidity of chronic kidney disease (CKD) warrant effective strategies for identifying those at increased risk. We examined the association of cystatin C level and albuminuria with the development of CKD stage 3. Study Design: Prospective observational study. Setting & Participants: 5,422 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Predictor: Participants were categorized into 4 mutually exclusive groups: the presence or absence of microalbuminuria (albumin-creatinine ratio >17 and >25 μg/mg in men and women, respectively) in those with or without cystatin C level <1.0 mg/L. Outcomes & Measurements: Incident CKD stage 3 was defined as eGFR <60 mL/min/1.73 m2 at the third or fourth visit and an annual decrease >1 mL/min/1.73 m2. Poisson regression was used to evaluate incident rate ratios in unadjusted and adjusted analyses that include baseline eGFR. Results: Mean age was 61 years, 49% were men, 38% were white, 11% had diabetes, 13.7% had cystatin C level <1 mg/L, 8.4% had microalbuminuria, and 2.7% had cystatin C level <1 mg/L with microalbuminuria. 554 (10%) participants developed CKD stage 3 during a median follow-up of 4.7 years, and adjusted incidence rate ratios were 1.57 (95% CI, 1.19-2.07), 1.37 (95% CI, 1.13-1.66), and 2.12 (95% CI, 1.61-2.80) in those with microalbuminuria, cystatin C level <1 mg/L, and both, respectively, compared with those with neither. Limitations: Relatively short follow-up and absence of measured GFR. Conclusions: Cystatin C level and microalbuminuria are independent risk factors for incident CKD stage 3 and could be useful as screening tools to identify those at increased risk.

AB - Background: The growing burden and morbidity of chronic kidney disease (CKD) warrant effective strategies for identifying those at increased risk. We examined the association of cystatin C level and albuminuria with the development of CKD stage 3. Study Design: Prospective observational study. Setting & Participants: 5,422 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Predictor: Participants were categorized into 4 mutually exclusive groups: the presence or absence of microalbuminuria (albumin-creatinine ratio >17 and >25 μg/mg in men and women, respectively) in those with or without cystatin C level <1.0 mg/L. Outcomes & Measurements: Incident CKD stage 3 was defined as eGFR <60 mL/min/1.73 m2 at the third or fourth visit and an annual decrease >1 mL/min/1.73 m2. Poisson regression was used to evaluate incident rate ratios in unadjusted and adjusted analyses that include baseline eGFR. Results: Mean age was 61 years, 49% were men, 38% were white, 11% had diabetes, 13.7% had cystatin C level <1 mg/L, 8.4% had microalbuminuria, and 2.7% had cystatin C level <1 mg/L with microalbuminuria. 554 (10%) participants developed CKD stage 3 during a median follow-up of 4.7 years, and adjusted incidence rate ratios were 1.57 (95% CI, 1.19-2.07), 1.37 (95% CI, 1.13-1.66), and 2.12 (95% CI, 1.61-2.80) in those with microalbuminuria, cystatin C level <1 mg/L, and both, respectively, compared with those with neither. Limitations: Relatively short follow-up and absence of measured GFR. Conclusions: Cystatin C level and microalbuminuria are independent risk factors for incident CKD stage 3 and could be useful as screening tools to identify those at increased risk.

KW - Albuminuria

KW - chronic kidney disease

KW - cystatin C

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=79956339923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956339923&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2010.11.021

DO - 10.1053/j.ajkd.2010.11.021

M3 - Article

VL - 57

SP - 832

EP - 840

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 6

ER -